The Science Behind XEOMIN

Purifying Botulinum Toxin Type A Into XEOMIN

XTRACT TechnologyTM is the only state-of-the-art manufacturing process that uniquely purifies the molecule removing the unnecessary proteins, leaving just the active therapeutic component.*

Neurotoxin separated from accessory proteins
Botulinum toxin type A
is produced from Hall
strain Clostridium
botulinum serotype A1
Neurotoxin separated from accessory proteins
Unnecessary
proteins are
separated by
chromatography
Neurotoxin separated from accessory proteins
Producing a
unique, purified
molecule

*The direct impact of the non-therapeutic proteins on long term safety or efficacy has not been established. Information about the unique XEOMIN manufacturing process and the properties of incobotulinumtoxinA is not intended to imply superiority over other botulinum toxin type A products.

XEOMIN Manufacturing Video

XEOMIN Patients Did Not Develop Clinical Resistance Due to Neutralizing Antibodies (NAb)1

  • Of the 1490 patients treated with XEOMIN in placebo-controlled clinical trials across all indications, no patients demonstrated clinical resistance or secondary treatment failure due to NAb1†
Patient graphic showing clinical trial results

†In placebo-controlled clinical trials for all approved indications.

XEOMIN Has a Molecular Weight of 150 kDa

150kDa XEOMIN® Molecule

150 kDa XEOMIN Molecule2

  • The proprietary manufacturing process of XEOMIN isolates the active neuromodulator from the accessory proteins and reduces the number of proteins1-3
  • XEOMIN is formulated to have high biological activity with a low protein load1-3
Molecular weights of botulinum toxins less with XEOMIN®
  • The direct impact of the non-therapeutic proteins on long term safety or efficacy has not been established. Information about the unique XEOMIN manufacturing process and the properties of incobotulinumtoxinA is not intended to imply superiority over other botulinum toxin type A products
  • The potency Units of XEOMIN are specific to the preparation and assay method used and are not interchangeable with other preparations of botulinum toxin products. Therefore, Units of biological activity of XEOMIN cannot be compared to or converted into Units of any other botulinum toxin products

XEOMIN Mechanism of Action

XEOMIN is a botulinum toxin type A that blocks transmission at the neuromuscular junction by inhibiting the release of acetylcholine from peripheral cholinergic nerve endings1

XEOMIN Mechanism of Action Video

References

  1. XEOMIN® [Package insert]. Raleigh, NC: Merz Pharmaceuticals, LLC; 2019.
  2. Dressler D, Benecke R. Pharmacology of therapeutic botulinum toxin preparations. Disabil Rehabil. 2007;29(23):1761-1768.
  3. Dressler D. Botulinum toxin drugs: future developments. J Neural Transm. 2008;115(4):575-577.